Filing Analysis
Iterum Therapeutics plc has filed a petition in the High Court in Ireland to wind up the company and is withdrawing its appeal against Nasdaq delisting. The company has appointed joint provisional liquidators and expects to cease all future SEC filings, including its 2025 Annual Report.
Red Flags
- Winding up petition (liquidation) filed in Ireland.
- Immediate delisting from Nasdaq following withdrawal of appeal.
- Cessation of all future SEC reporting obligations.
- Appointment of provisional liquidators to oversee the dissolution of the company.
- Explicit statement regarding limited cash resources.
Key Facts
- Filed a petition in the High Court in Ireland to wind up the company on March 27, 2026.
- Withdrew appeal of Nasdaq delisting determination on March 30, 2026.
- Trading of ordinary shares will be suspended on Nasdaq at the opening of business on April 1, 2026.
- Damien Murran and Jennifer McMahon of Teneo Restructuring (Ireland) Limited appointed as joint provisional liquidators.
- Company stated it does not expect to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, or any future SEC filings.
- The company cited 'limited cash resources' as a primary driver for the winding up process.
Iterum Therapeutics plc has filed a petition in the High Court in Ireland to wind up the company and has appointed Joint Provisional Liquidators. This action has triggered an immediate resignation of the CEO and CFO, an event of default on its Royalty-Linked Subordinated Notes, and an expected total loss for shareholders.
Red Flags
- Liquidation/Winding up petition filed.
- Immediate resignation of the entire top executive suite (CEO and CFO).
- Event of default on debt obligations.
- Warning of total loss for equity holders.
- Imminent delisting from Nasdaq.
Key Facts
- Filed a Winding Up Petition in the High Court in Ireland on March 27, 2026.
- Damien Murran and Jennifer McMahon of Teneo Restructuring appointed as Joint Provisional Liquidators.
- CEO Corey Fishman and CFO Judith Matthews resigned effective March 27, 2026.
- The filing triggered an event of default on the company's Limited Recourse Royalty-Linked Subordinated Notes dated January 21, 2020.
- Default interest on the notes is now Prime + 3%.
- Nasdaq trading suspension expected to be effective as of March 27, 2026.
- Company warns securityholders to expect a 'significant or complete loss on their investment'.
Iterum Therapeutics requested a hearing to appeal a Nasdaq delisting notice regarding its failure to maintain a $1.00 minimum bid price. The company also disclosed non-compliance with the $35 million minimum market value requirement and warned of a potential wind-down or bankruptcy where shareholders would likely receive no return.
Red Flags
- Explicit warning that shareholders are 'very unlikely to receive any meaningful distribution' in a potential liquidation.
- Multiple Nasdaq non-compliance issues (bid price and $35M market value).
- Company admits to 'limited ability to raise additional capital' and 'limited time and available resources'.
- Possibility of a wind-down or bankruptcy filing explicitly mentioned.
Key Facts
- Received Nasdaq delisting determination letter on February 24, 2026, due to failure to maintain $1.00 minimum bid price.
- Requested a hearing before the Nasdaq Hearings Panel on March 3, 2026, which stays the delisting action temporarily.
- Currently fails to meet Nasdaq Listing Rule 5550(b)(2) requiring a minimum market value of listed securities of $35 million.
- Compliance deadline for the $35 million market value requirement is June 9, 2026.
- Management is evaluating strategic alternatives including licensing, sale, or a potential bankruptcy/liquidation proceeding.
Iterum Therapeutics received a Nasdaq delisting determination letter on February 24, 2026, due to continued non-compliance with the $1.00 minimum bid price rule. The company's shares are scheduled for suspension on March 5, 2026, and management is openly discussing the possibility of bankruptcy, liquidation, or a total wind-down of operations.
Red Flags
- Imminent delisting and suspension of trading on Nasdaq.
- Explicit mention of potential bankruptcy, liquidation, or dissolution.
- Warning of total loss for shareholders.
- Potential filing of Form 15 to cease SEC reporting obligations.
- Limited ability to raise additional capital.
Key Facts
- Nasdaq issued a delisting determination letter on February 24, 2026.
- Trading suspension is scheduled for the open of business on March 5, 2026.
- The company is non-compliant with the $1.00 minimum bid price rule (Rule 5550(a)(2)).
- The company is also non-compliant with the $35 million Minimum Market Value of Listed Securities (MVLS) requirement.
- Management stated that shareholders are 'very unlikely to receive any meaningful distribution or return' in a potential liquidation.